Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges

Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges

CoinpediaCoinpedia2026/09/05 19:30
By:Coinpedia
Story Highlights
  • Aerodrome’s tokenized stock trading volume surpassed $250 million in two weeks.

  • Revenue improved, but the emissions-to-revenue ratio rose to 1.75.

  • AERO faces $0.54 resistance, with $0.85 and $0.30 as key future levels.

Aerodrome’s tokenized stock trading volume has crossed $250 million in just two weeks. If the histogram trend continues, $300 million could be the next target for Aerodrome on Base. The numbers are getting attention, but the token still has plenty to prove.

Aerodrome Stock Trading Gains Fresh Momentum

Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges image 0

The newly available stocks include Amazon, Microsoft, Strategy, SanDisk, SpaceX and Tesla. That gives users access to a broader selection of familiar names through Aerodrome’s marketplace, although higher trading volume alone doesn’t guarantee stronger token performance.

The next measurable milestone is $300 million. Based on the rising histogram, that level could arrive if the current trading trend continues.

Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges image 1

Aerodrome Revenue Improves, But Emissions Matter

Blockworks’ dashboard shows Aerodrome revenue increasing during the latest week, with the histogram indicating improving business activity. For AERO holders, that suggests revenue generation has been moving in a more positive direction.

However, the emissions-to-revenue ratio has also risen. Based on the latest epoch, the ratio stands at 1.75, compared with a low of 0.29. That means emissions remain a significant factor when assessing the protocol’s economics.

Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges image 2

Aerodrome’s net income has improved substantially from its earlier losses. Between November 29 and December 5, 2024, weekly losses reached approximately $10 million. In 2026, net income has hovered around negative $1 million, but the broader trend shows a clear reduction in losses. That’s progress. But, It’s just not the same as consistent profitability.

AERO Price Still Faces Major Resistance Levels

AERO’s long-term price action remains trapped within a broad falling wedge that began after the April 2024 peak near $2.35. A late-2024 rally retested that resistance but failed to break it decisively.

The bear market then pushed AERO/USD toward the $0.30 demand area in 2025. A recovery followed, reaching approx. $1.60 by August 2025, before another decline sent the token back toward $0.30 in early February 2026.

This time, the recovery has been slower. AERO price is now following an ascending trendline and testing the $0.54 resistance area during Q3 2026.

Aerodrome Price Eyes $0.85 as Stock Trading Volume Surges image 3

A successful breakout could open the way toward $0.85, followed by $1.20, $1.60 and potentially $2.35 by year-end. But the chart still offers several ways for bullish expectations to fail.

If $0.54 continues to reject price, then AERO price could finish the year below that level and revisit $0.30. Even a move above $0.54 and toward $0.85 wouldn’t settle the matter. Rejection at $0.85 could send the token back to $0.54, while losing that support could expose the $0.30 demand zone.

For now, Aerodrome has improving trading activity, better revenue trends and a major stock-market expansion. Whether those developments can push AERO token price beyond $0.54 remains the market’s next test.

Loading article prices

What is Aerodrome’s tokenized stock trading volume?

Aerodrome’s cumulative tokenized stock trading volume on Base surpassed $250 million in two weeks.

Which stocks are live on Aerodrome?

The marketplace now includes Amazon, Microsoft, Strategy, SanDisk, SpaceX and Tesla.

What is the next Aerodrome stock trading volume target?

If the current histogram trend continues, $300 million could be the next target.

Is Aerodrome revenue improving?

Yes, the latest Blockworks dashboard shows revenue increasing during the past week.

What is Aerodrome’s emissions-to-revenue ratio?

Aerodrome’s emissions-to-revenue ratio stands at 1.75, up from a low of 0.29.

What is the key AERO price resistance?

AERO is currently testing the $0.54 resistance area.

Could AERO price reach $0.85?

If AERO breaks above $0.54, the next potential resistance is around $0.85.

What happens if AERO loses support?

A rejection from $0.54 or $0.85 could send AERO back toward $0.30.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market